Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation
Clinical Endocrinology · 2025-03 · 102 (3) · 315-323
DOI: 10.1111/cen.15150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, online erschienen am 14.10.2024. Verfasst von Mohammad Jay und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Atrial Fibrillation, Hyperthyroidism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Context
Treating overt hyperthyroidism prevents atrial fibrillation (AF). Though subclinical hyperthyroidism (SH) has been associated with AF, it is unknown whether treating SH prevents AF.
Objective
We aimed to identify the association between treating SH and incident AF.
Design
In a pharmacoepidemiologic retrospective cohort study, patients diagnosed with SH between 2000 and 2021 were followed. Patients Outpatients ≥ 18 years with biochemical SH and without prior AF, hypothyroidism, thyroid cancer, pituitary disease, or pregnancy were included. Main Outcomes The primary outcome was incident AF. Secondary outcomes were ECG and echocardiographic features associated with AF.
Results
Of 2169 patients screened, 360 (131 treated and 229 untreated) were followed up for a mean of 4.27 years. In the treated and untreated groups, AF occurred in 4 (3.1%) and 15 (6.6%) patients ( p = 0.15), and AF incidence was 0.8% and 1.4%/year ( p = 0.31), respectively. The hazard ratio (HR) for treatment as a time‐dependent variable was 0.60 (95% CI 0.19–1.92; p = 0.39). As some cases of AF were documented nearly simultaneously with SH treatment, a sensitivity analysis was performed reassigning two patients diagnosed with AF < 30 days after starting SH treatment to the untreated group. Here, in the treated and untreated groups, AF occurred in 1.6% and 7.4% ( p = 0.02), and AF incidence was 0.4% and 1.8%/year ( p = 0.02), respectively. The HR was 0.25 (0.06–1.13; p = 0.07). There were no differences in ECG or echocardiographic features.
Conclusion
There was an overall trend towards lower incidence and prevalence of AF following treatment of SH, supporting the need for larger scale studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, University of Toronto, Toronto, Ontario, Canada.
- Faculty of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
- Department of Medicine, Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Zubin Punthakee
Zitieren
APA
Jay, M., Huan, P., Cliffe, N., Rakoff, J., Morris, E., Kavsak, P., Luthra, M., & Punthakee, Z. (2025). Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation. Clinical Endocrinology, 102(3), 315-323. https://doi.org/10.1111/cen.15150
Vancouver
Jay M, Huan P, Cliffe N, Rakoff J, Morris E, Kavsak P, et al. Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation. Clinical Endocrinology. 2025;102(3):315-323. doi:10.1111/cen.15150
BibTeX
@article{Jay2025,
author = {Jay, Mohammad and Huan, Peter and Cliffe, Nikki and Rakoff, Jonah and Morris, Emily and Kavsak, Peter and Luthra, Meera and Punthakee, Zubin},
title = {Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation},
journal = {Clinical Endocrinology},
year = {2025},
volume = {102},
number = {3},
pages = {315--323},
doi = {10.1111/cen.15150}
}
EUVIMED